Page 111 - 2020_01-Haematologica-web

Myeloablative MSD-SCT for SCA: long-term outcome
Transplantation in Children with Hemoglobinopathies. Biol Blood Marrow Transplant. 2017;23(9):1531-1540.
35. Powell JD, Lerner CG, Schwartz RH.Inhibition of cell cycle progression by rapamycin induces T cell clonal anergy even in the presence of costimulation. J Immunol. 1999;162(5):2775-2784.
36. Brugieres L, Hartmann O, Travagli JP, et al. Hemorrhagic Cystitis Following High- Dose Chemotherapy and Bone-Marrow Transplantation in Children with Malignancies - Incidence, Clinical Course, and Outcome. J Clin Oncol. 1989;7(2):194- 199.
37. Lunde LE, Dasaraju S, Cao Q, et al. Hemorrhagic cystitis after allogeneic hematopoietic cell transplantation: risk factors, graft source and survival. Bone Marrow Transplant. 2015;50(11):1432- 1437.
38. Bartelink IH, van Reij EM, Gerhardt CE, et al. Fludarabine and exposure-targeted busulfan compares favorably with busul- fan/cyclophosphamide-based regimens in pediatric hematopoietic cell transplanta- tion: maintaining efficacy with less toxici- ty. Biol Blood Marrow Transplant. 2014; 20(3):345-353.
39. Harris AC, Boelens JJ, Ahn KW, et al. Comparison of pediatric allogeneic trans- plant outcomes using myeloablative busul- fan with cyclophosphamide or fludara- bine. Blood Adv. 2018;2(11):1198-1206.
40. Sanders JE, Hawley J, Levy W, et al. Pregnancies following high-dose cyclophosphamide with or without high- dose busulfan or total-body irradiation and bone marrow transplantation. Blood. 1996; 87(7):3045-3052.
41. Vatanen A, Wilhelmsson M, Borgström B, et al. Ovarian function after allogeneic hematopoietic stem cell transplantation in childhood and adolescence. Eur J Endocrinol. 2013;170(2):211-218.
42. Poirot C, Abirached F, Prades M, Coussieu C, Bernaudin F, Piver P. Induction of puber- ty by autograft of cryopreserved ovarian tissue. Lancet. 2012;379(9815):588.
43. Donnez J, Dolmans MM, Demylle D, et al. A. Livebirth after orthotopic transplanta- tion of cryopreserved ovarian tissue. Lancet. 2004;364(9443):1405-1410. Erratum in: Lancet. 2004;364(9450):2020.
44. Baert Y, Van Saen D, Haentjens P, In't Veld P, Tournaye H, Goossens E. What is the best cryopreservation protocol for human testicular tissue banking? Hum Reprod.
2013;28(7):1816-1826.
45. Smith-Whitley K. Reproductive issues in
sickle cell disease. Blood. 2014; 124(24):
3538-3543.
46. Walters MC, Patience M, Leisenring, et al.
Stable mixed hematopoietic chimerism after bone marrow transplantation for sickle cell anemia. Biol Blood Marrow Transplant. 2001;7(12):665-673.
47. Hsieh MM, Wu CJ, Tisdale JF. In mixed hematopoietic chimerism, the donor red cells win. Haematologica. 2011;96(1):13-15.
48. Fitzhugh CD, Cordes S, Taylor T, et al. At least 20% donor myeloid chimerism is necessary to reverse the sickle phenotype after allogeneic HSCT. Blood. 2017;130(17):1946-1948.
49. Abraham A, Hsieh M, Eapen M, et al. Relationship between Mixed Donor- Recipient Chimerism and Disease Recurrence after Hematopoietic Cell Transplantation for Sickle Cell Disease. Biol Blood Marrow Transplant. 2017;23(12):2178-2183.
50. Bernaudin F, Pondarré C, Galambrun C, Thuret I. Allogeneic/Matched Related Transplantation for β-Thalassemia and Sickle Cell Anemia. Adv Exp Med Biol. 2017;1013:89-122.
haematologica | 2020; 105(1)
101